{"entity":{"id":"urethral","kind":"cancer","name":"Urethral cancer","aka":["Primary urethral carcinoma","Carcinoma of the urethra"],"tldr":"Urethral cancer grows in the tube that carries urine out of the body, with fewer than one case per million people a year. With no randomised trials, it is treated by borrowing from bladder, anal or vulvar cancer depending on cell type and location; chemotherapy with radiotherapy before or instead of surgery lets more patients keep their organs.","summary":"Primary urethral carcinoma is defined by where in the urethra it starts and by the lining it arises from: urothelial carcinoma in the prostatic and proximal urethra, squamous cell carcinoma in the distal (penile or anterior) urethra, and adenocarcinoma, often of Skene or Littre gland origin or arising in a diverticulum, particularly in women. Risk factors include chronic stricture and inflammation, prior radiotherapy, urethral diverticulum and HPV infection for squamous tumours. Presentation is with bleeding, obstruction or a palpable mass, and diagnosis is frequently delayed because symptoms mimic stricture or infection.\n\nThere are no randomised trials. Distal tumours are treated with organ-sparing surgery (partial urethrectomy or distal penectomy in men; distal urethrectomy in women) or with radiotherapy; proximal and locally advanced tumours have historically required radical cystoprostatectomy or anterior exenteration, but the modern approach favours neoadjuvant or definitive platinum-based chemotherapy with or without radiotherapy, extrapolated from bladder cancer (cisplatin-based combinations for urothelial histology) and anal or vulvar cancer (mitomycin or cisplatin with fluorouracil and radiotherapy for squamous histology). Multi-institutional series such as those from the international collaboration on primary urethral carcinoma show better survival with multimodal therapy than with surgery alone, and the EAU has published a dedicated guideline.\n\nThe practical frontier is applying advances from urothelial cancer (enfortumab vedotin with pembrolizumab, checkpoint inhibitors) and HPV-associated squamous cancers to this tiny population through basket trials and registries.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Urethral_cancer","links":[{"label":"NCI PDQ: urethral cancer","url":"https://www.cancer.gov/types/urethral"},{"label":"EAU Guidelines: Primary Urethral Carcinoma","url":"https://uroweb.org/guidelines/primary-urethral-carcinoma"}],"tags":["nci-coverage","rare","genitourinary"],"related":["urothelial","anal","vulvar","penile"],"cancers":[],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","brachytherapy","checkpoint-inhibitor","adc"],"targets":["pd1","nectin4","fgfr3"],"drugs":["cisplatin","gemcitabine-cisplatin","fluorouracil","mitomycin","enfortumab-vedotin","pembrolizumab"],"companies":[],"institutions":[],"pathways":["oncogenic-viruses"],"terms":["hpv-p16","chemoradiation"],"trials":[],"people":[],"bottlenecks":["b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"group":"genitourinary","burden":"One of the rarest genitourinary cancers, with fewer than one case per million per year in most registries; it is more common in men and in people over 60.","subtypes":["Urothelial carcinoma (proximal and prostatic urethra)","Squamous cell carcinoma (distal urethra; HPV-associated in some)","Adenocarcinoma (including clear cell adenocarcinoma of the female urethra)","Urethral melanoma (very rare)"],"biomarkers":["Histology and site (drives treatment analogy)","Clinical and MRI stage, nodal status","HPV / p16 in squamous tumours","PD-L1 and FGFR3 in urothelial histology (extrapolated from bladder cancer)","Urine cytology and urethroscopy findings"],"standardOfCare":[{"setting":"Distal, localised","approach":"Organ-sparing surgery (distal urethrectomy, partial penectomy) or radiotherapy including brachytherapy.","refs":["brachytherapy"],"guideline":{"version":"EAU Guidelines on Primary Urethral Carcinoma","url":"https://uroweb.org/guidelines/primary-urethral-carcinoma"}},{"setting":"Proximal or locally advanced","approach":"Neoadjuvant platinum-based chemotherapy (or chemoradiation for squamous histology) followed by surgery; definitive chemoradiation as organ-preserving alternative.","refs":["cisplatin","gemcitabine-cisplatin","fluorouracil","mitomycin","imrt-igrt"],"guideline":{"nccn":"Category 2A (in Bladder Cancer guideline, primary carcinoma of the urethra section)","version":"NCCN Guidelines: Bladder Cancer"}},{"setting":"Metastatic","approach":"Treat by histology: urothelial-type regimens (enfortumab vedotin plus pembrolizumab, gemcitabine-cisplatin) or squamous regimens; clinical trials.","refs":["enfortumab-vedotin","pembrolizumab","gemcitabine-cisplatin"]}],"stateOfArt":["Multimodal therapy (chemotherapy with radiotherapy or surgery) has largely replaced radical surgery alone, based on international retrospective collaborations.","Treatment is chosen by histology, borrowing the best evidence from bladder cancer for urothelial tumours and from anal and vulvar cancer for squamous tumours.","The EAU maintains the only dedicated guideline; registries and basket trials are the path to better evidence."],"history":[{"year":1834,"title":"First reported case of urethral carcinoma","note":"Thiaudierre's description in a woman.","refs":[]},{"year":2013,"title":"International collaboration on primary urethral carcinoma","note":"Gakis and colleagues pool multi-institutional data, showing benefit of perioperative chemotherapy and defining the EAU guideline.","refs":[]},{"year":2023,"title":"Enfortumab vedotin plus pembrolizumab approved for urothelial cancer","note":"Applied by extrapolation to urothelial-type urethral carcinoma.","refs":["enfortumab-vedotin","pembrolizumab"]}],"pipeline":["enfortumab-vedotin","pembrolizumab"],"openProblems":["No prospective trials; international registries and inclusion in urothelial and HPV-squamous basket trials are the response.","Late diagnosis mimicking benign stricture; urethroscopy for unexplained stricture or bleeding is the practical fix.","Balancing organ preservation with cure in proximal tumours; chemoradiation series are growing."]},"route":"/cancers/urethral/","neighbours":{"cancer":[{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/"},{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"urethral-melanoma","kind":"cancer","name":"Melanoma of the urethra","route":"/cancers/urethral-melanoma/"},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/"},{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/"},{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"term":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"},{"id":"fgfr3","kind":"term","name":"FGFR3 alterations (bladder cancer)","route":"/terms/fgfr3/"},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"},{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"pathway":[{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}]}}